Showing 2 posts of 2 posts found.
Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …
Forty Seven, a spinout from Stanford University, has had a busy few days – first announcing that it had filed …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO